The effects of dexmedetomidine on inflammatory mediators after cardiopulmonary bypass

Anaesthesia

Volumn 69, Issue 7, 2014, Pages 693-700

  Ueki, M ^a   Kawasaki, T ^a   Habe, K ^a   Hamada, K ^a   Kawasaki, C ^a   Sata, T ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATINE KINASE; CREATINE KINASE MB; DEXMEDETOMIDINE; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; NITROGEN; SODIUM CHLORIDE; TRANEXAMIC ACID;

ABSENCE OF SIDE EFFECTS; AGED; AORTA CLAMPING; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; FEMALE; HEART FUNCTION; HUMAN; INFLAMMATION; INFUSION; KIDNEY FUNCTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LIVER FUNCTION; MALE; NEUTROPHIL; NITROGEN URINE LEVEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANALGESICS, NON-NARCOTIC; BIOLOGICAL MARKERS; CARDIOPULMONARY BYPASS; DEXMEDETOMIDINE; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; NF-KAPPA B; POSTOPERATIVE CARE; PROSPECTIVE STUDIES; SODIUM CHLORIDE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 84902539326     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/anae.12636     Document Type: Article

References (41)

1. Asimakopoulos G,. Systemic inflammation and cardiac surgery: an update. Perfusion 2001; 16: 353-60.
2. Paparella D, Yau TM, Young E,. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Europian Journal of Cardiothoracic Surgery 2002; 21: 232-44.
3. Suleiman MS, Zacharowski K, Angelini GD,. Inflammatory response and cardioprotection during open-heart surgery: the importance of anaesthetics. British Journal of Pharmacology 2008; 153: 21-33.
4. Murphy GJ, Angelini GD,. Side effects of cardiopulmonary bypass: what is the reality? Journal of Cardiac Surgery 2004; 19: 481-8.
5. Zahler S, Massoudy P, Hartl H, Hahnel C, Meisner H, Becker BF,. Acute cardiac inflammatory responses to postischemic reperfusion during cardiopulmonary bypass. Cardiovascular Research 1999; 41: 722-30.
6. Sander M, von Heymann C, von Dossow V, et al. Increased interleukin-6 after cardiac surgery predicts infection. Anesthesia and Analgesia 2006; 102: 1623-9.
7. Spies CD, Kern H, Schroder T, et al. Myocardial ischemia and cytokine response are associated with subsequent onset of infections after noncardiac surgery. Anesthesia and Analgesia 2002; 95: 9-18.
8. Nieman G, Searles B, Carney D, et al. Systemic inflammation induced by cardiopulmonary bypass: a review of pathogenesis and treatment. Journal of Extra-Corporeal Technology 1999; 31: 202-10.
9. Jordan JE, Zhao ZQ, Vinten-Johansen J,. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovascular Research 1999; 43: 860-78.
10. Sanders RD, Hussell T, Maze M,. Sedation & immunomodulation. Critical Care Clinics 2009; 25: 551-70.
11. Qiao H, Sanders RD, Ma D, Wu X, Maze M,. Sedation improves early outcome in severely septic Sprague Dawley rats. Critical Care 2009; 13: R136.
12. Taniguchi T, Kidani Y, Kanakura H, Takemoto Y, Yamamoto K,. Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats. Critcal Care Medicine 2004; 32: 1322-6.
13. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-51.
14. Tsung A, Sahai R, Tanaka H, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. Journal of Experimental Medicine 2005; 201: 1135-43.
15. Wan S, Yim AP,. Cytokines in myocardial injury: impact on cardiac surgical approach. Europian Journal of Cardiothoracic Surgery 1999; 16 (Suppl 1): S107-11.
16. Haque A, Kunimoto F, Narahara H, et al. High mobility group box 1 levels in on and off-pump cardiac surgery patients. International Heart Journal 2011; 52: 170-4.
17. Andrassy M, Volz HC, Igwe JC, et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008; 117: 3216-26.
18. Tzeng HP, Fan J, Vallejo JG, et al. Negative inotropic effects of high-mobility group box 1 protein in isolated contracting cardiac myocytes. American Journal of Physiology Heart and Circulatory Physiology 2008; 294: H1490-6.
19. Abarbanell AM, Hartley JA, Herrmann JL, et al. Exogenous high-mobility group box 1 improves myocardial recovery after acute global ischemia/reperfusion injury. Surgery 2011; 149: 329-35.
20. Oozawa S, Mori S, Kanke T, et al. Effects of HMGB1 on ischemia-reperfusion injury in the rat heart. Circulation Journal 2008; 72: 1178-84.
21. Oyama J, Blais C Jr, Liu X, et al. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 2004; 109: 784-9.
22. Shimamoto A, Chong AJ, Yada M, et al. Inhibition of toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation 2006; 114 (1 Suppl): I270-4.
23. Bucciarelli LG, Kaneko M, Ananthakrishnan R, et al. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation 2006; 113: 1226-34.
24. Goldstein RS, Gallowitsch-Puerta M, Yang L, et al. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 2006; 25: 571-4.
25. Cirillo P, Giallauria F, Pacileo M, et al. Increased high mobility group box-1 protein levels are associated with impaired cardiopulmonary and echocardiographic findings after acute myocardial infarction. Journal of Cardiac Failure 2009; 15: 362-7.
26. Kitahara T, Takeishi Y, Harada M, et al. High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice. Cardiovascular Research 2008; 80: 40-6.
27. Limana F, Germani A, Zacheo A, et al. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circulation Research 2005; 97: e73-83.
28. Venn RM, Bryant A, Hall GM, Grounds RM,. Effects of dexmedetomidine on adrenocortical function, and the cardiovascular, endocrine and inflammatory responses in post-operative patients needing sedation in the intensive care unit. British Journal of Anaesthesia 2001; 86: 650-6.
29. Tasdogan M, Memis D, Sut N, Yuksel M,. Results of a pilot study on the effects of propofol and dexmedetomidine on inflammatory responses and intraabdominal pressure in severe sepsis. Journal of Clinical Anesthesia 2009; 21: 394-400.
30. Pandharipande PP, Sanders RD, Girard TD, et al. Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial. Critical Care 2010; 14: R38.
31. Gu J, Sun P, Zhao H, et al. Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice. Critical Care 2011; 15: R153.
32. Valen G, Paulsson G, Vaage J,. Induction of inflammatory mediators during reperfusion of the human heart. Annual of Thoracic Surgery 2001; 71: 226-32.
33. Fischer UM, Antonyan A, Bloch W, Mehlhorn U,. Impact of antioxidative treatment on nuclear factor kappa-B regulation during myocardial ischemia-reperfusion. Interactive Cardiovascular and Thoracic Surgery 2006; 5: 531-5.
34. Kawasaki T, Kawasaki C, Ueki M, Hamada K, Habe K, Sata T,. Dexmedetomidine suppresses proinflammatory mediator production in human whole blood in vitro. Journal of Trauma and Acute Care Surgery 2013; 74: 1370-5.
35. van Zoelen MA, Yang H, Florquin S, et al. Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 2009; 31: 280-4.
36. Okada H, Kurita T, Mochizuki T, Morita K, Sato S,. The cardioprotective effect of dexmedetomidine on global ischaemia in isolated rat hearts. Resuscitation 2007; 74: 538-45.
37. Welbourn N, Melrose DG, Moss DW,. Changes in serum enzyme levels accompanying cardiac surgery with extracorporeal circulation. Journal of Clinical Pathology 1966; 19: 220-32.
38. Whitlock RP, Rubens FD, Young E, Teoh KH,. Pro: steroids should be used for cardiopulmonary bypass. Journal of Cardiothoracic and Vascular Anesthesia 2005; 19: 250-4.
39. Morariu AM, Loef BG, Aarts LP, et al. Dexamethasone: benefit and prejudice for patients undergoing on-pump coronary artery bypass grafting: a study on myocardial, pulmonary, renal, intestinal, and hepatic injury. Chest 2005; 128: 2677-87.
40. Lin YY, He B, Chen J, Wang ZN,. Can dexmedetomidine be a safe and efficacious sedative agent in post-cardiac surgery patients? a meta-analysis. Critical Care 2012; 16: R169.
41. Ji F, Li Z, Nguyen H, et al. Perioperative dexmedetomidine improves outcomes of cardiac surgery. Circulation 2013; 127: 1576-84.